DE69018799D1 - IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie. - Google Patents

IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.

Info

Publication number
DE69018799D1
DE69018799D1 DE69018799T DE69018799T DE69018799D1 DE 69018799 D1 DE69018799 D1 DE 69018799D1 DE 69018799 T DE69018799 T DE 69018799T DE 69018799 T DE69018799 T DE 69018799T DE 69018799 D1 DE69018799 D1 DE 69018799D1
Authority
DE
Germany
Prior art keywords
igf
treatment
side effects
steroid therapy
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69018799T
Other languages
English (en)
Other versions
DE69018799T2 (de
Inventor
Ronald L Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of DE69018799D1 publication Critical patent/DE69018799D1/de
Application granted granted Critical
Publication of DE69018799T2 publication Critical patent/DE69018799T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69018799T 1989-12-22 1990-12-13 IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie. Expired - Fee Related DE69018799T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45521589A 1989-12-22 1989-12-22

Publications (2)

Publication Number Publication Date
DE69018799D1 true DE69018799D1 (de) 1995-05-24
DE69018799T2 DE69018799T2 (de) 1995-09-21

Family

ID=23807878

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69018799T Expired - Fee Related DE69018799T2 (de) 1989-12-22 1990-12-13 IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.

Country Status (14)

Country Link
EP (1) EP0434625B1 (de)
JP (1) JP2934023B2 (de)
KR (1) KR100191381B1 (de)
AT (1) ATE121296T1 (de)
AU (1) AU641966B2 (de)
CA (1) CA2032859C (de)
DE (1) DE69018799T2 (de)
DK (1) DK0434625T3 (de)
ES (1) ES2071080T3 (de)
GR (1) GR3015900T3 (de)
IE (1) IE67510B1 (de)
IL (1) IL96711A (de)
NZ (1) NZ236614A (de)
ZA (1) ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH10504971A (ja) * 1994-09-08 1998-05-19 カイロン コーポレイション インスリン様増殖因子の改善された生産方法
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU7271996A (en) * 1995-10-23 1997-05-15 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
WO1998011913A1 (en) * 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
JP2002510646A (ja) 1998-04-03 2002-04-09 カイロン コーポレイション 関節軟骨障害を処置するためのｉｇｆｉの使用
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DK1282437T3 (da) 2000-05-16 2008-06-30 Genentech Inc Behandling af brusklidelser
US8119591B2 (en) 2005-08-01 2012-02-21 Genera Istrazivanja D.O.O. Methods and compositions for regenerating articular cartilage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE88899T1 (de) * 1986-11-14 1993-05-15 Inst Molecular Biology Inc Wundheilung und knochenregeneration.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β

Also Published As

Publication number Publication date
CA2032859A1 (en) 1991-06-23
IE904684A1 (en) 1991-07-17
IE67510B1 (en) 1996-04-03
ES2071080T3 (es) 1995-06-16
NZ236614A (en) 1993-10-26
ATE121296T1 (de) 1995-05-15
GR3015900T3 (en) 1995-07-31
KR910011279A (ko) 1991-08-07
CA2032859C (en) 2007-09-17
JP2934023B2 (ja) 1999-08-16
EP0434625A2 (de) 1991-06-26
DE69018799T2 (de) 1995-09-21
KR100191381B1 (ko) 1999-06-15
EP0434625A3 (en) 1991-10-02
DK0434625T3 (da) 1995-06-26
JPH04210648A (ja) 1992-07-31
ZA9010332B (en) 1991-08-28
EP0434625B1 (de) 1995-04-19
IL96711A (en) 1996-01-19
IL96711A0 (en) 1991-09-16
AU6824790A (en) 1991-06-27
AU641966B2 (en) 1993-10-07

Similar Documents

Publication Publication Date Title
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69016768D1 (de) Zusammensetzung und Verfahren für die Behandlung von Osteoporose bei Säugetieren.
DE69327402D1 (de) Vorbeugung und behandlung der peripheren neuropathie
ATE186840T1 (de) Zusammensetzungen und methoden zur wundbehandlung
ES2113857T3 (es) Composiciones osteoinductoras.
DE69528058D1 (de) Bmp-9 zusammensetzungen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE3677400D1 (de) Verfahren zur behandlung von knochenersatz-implantaten.
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
DE3851584D1 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis
ATE127118T1 (de) 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee